NeuroSense Therapeutics (NRSN) Assets Average (2022 - 2025)
NeuroSense Therapeutics (NRSN) posted Assets Average of $1.4 million for Q4 2025, down 56.67% sequentially from $3.1 million in Q2 2025, and down 51.21% YoY from $2.8 million in Q4 2024.
NeuroSense Therapeutics (NRSN) Assets Average (2022 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Assets Average for 4 years, with the latest figure at $1.4 million in Q4 2025.
- Quarterly Assets Average fell 51.21% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 51.21% YoY) and the FY2025 annual result came in at $2.8 million, down 27.8% from the prior year.
- Assets Average eased to $1.4 million in Q4 2025 per NRSN's latest filing, from $3.1 million in the prior quarter.
- Over five years, Assets Average peaked at $12.9 million in Q2 2022 and troughed at $1.4 million in Q4 2025.
- A 4-year average of $5.8 million and a median of $5.4 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average plunged 78.69% in 2024, then surged 90.42% in 2025.
- Over 4 years, Assets Average stood at $8.5 million in 2022, then plunged by 49.42% to $4.3 million in 2023, then sank by 35.14% to $2.8 million in 2024, then slumped by 51.21% to $1.4 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $1.4 million, $3.1 million, and $2.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 1.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.36 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Dec 31, 2024 | 2.78 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Mar 31, 2024 | 2.32 Mn |
| Dec 31, 2023 | 4.29 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | 6.60 Mn |
| Mar 31, 2023 | 6.53 Mn |
| Dec 31, 2022 | 8.47 Mn |
| Sep 30, 2022 | 10.34 Mn |
| Jun 30, 2022 | 12.91 Mn |
| Mar 31, 2022 | 12.89 Mn |